Ideaya Biosciences, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.ideayabio.com

Market Cap $2.21B
PE -12
Debt $NaN
Cash $401.19M
EV $NaN
FCF -$153.27M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$178.12M
EBIT	-$224.75M
ROE	-15%
ROA	-18%
FCF	-$153.27M
Equity	$1.18B
Growth Stability	1
PE	-12.43
PB	1.88
P/FCF	-14.44
P/S	564.37
Price/Cash	0.18
Op. Margins	-6K%
Sales Growth YoY	-100%
Sales CAGR	-8%
Equity CAGR	51%
Earnings Growth YoY	89%

Earnings Growth QoQ	-2%
Sales CAGR 5Y	-24%
Equity CAGR 5Y	56%
Earnings CAGR 3Y	-44%
Sales CAGR 3Y	-44%
Equity CAGR 3Y	71%
Market Cap	$2.21B
Revenue	$3.92M
Assets	$1.24B
Cash	$401.19M
Shares Outstanding	79.65M
Working Capital	891.56M
Current Ratio	22.93
Shares Growth 3y	37%
Equity Growth QoQ	27%
Equity Growth YoY	132%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

SEC Filings

Direct access to Ideaya Biosciences, Inc. (IDYA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Ideaya Biosciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Ideaya Biosciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Ideaya Biosciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Ideaya Biosciences, Inc..

Years

Calculation mode

= -$1.5B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$153M	-$153M	-$153M	-$153M	-$153M	-$153M	-$153M	-$153M	-$153M	-$153M	-$153M	-$1.5B
DCF		-$139M	-$127M	-$115M	-$105M	-$95M	-$87M	-$79M	-$72M	-$65M	-$59M	-$591M
Value	-$1.5B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-177%	-178%	-115%	-483%	-
ROA	-	-38%	-39%	-12%	-13%	-16%	-21%	-18%
ROE	-	70%	-42%	-17%	-17%	-17%	-18%	-15%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	43%	82%	-54%	-24%
Earnings YoY growth	-	190%	22%	-18%	44%	18%	93%	-
Equity YoY growth	-	211%	-305%	97%	52%	16%	78%	56%
FCF YoY growth	-	110%	39%	-235%	-206%	55%	30%	-